- Email: [email protected]
Biomarker profiles for individual risk assessment and prostate cancer prevention
Biomarker Prevention
Profiles
for Individual
Risk
Assessment
and Prostate
Cancer
George P. Hemstreet, III, MD, PhD, Omaha, NE Recent results demonstrating the effectiveness of Finesteride for preventing or delaying prostate cancer and on going clinical studies such as the SELECT Trial emphasize the need for identifying and monitoring patients for chemoprevention therapy. Molecular “fingerprints” in organs at risk for cancer years in advance of clinically manifest disease can be detected utilizing single cell proteomics. Single cell proteomics provides the opportunity not only to study protein profiles in single cells but the ability to elucidate signaling pathways relevant to the premalignant process and the identification of molecular pathways relevant to treatment selection. The objective of this presentation is to provide a succinct overview of our experience with the selection of biomarkers for prostate cancer. Spectroscopy provides an accurate and sensitive method for quantitative single cell proteomics. Improved and more stable fluorescence probes and improved quantitative analysis of protein markers at the single cell level will enhance the utility of cellular chemistry. Single cell proteomics also facilitate the study of genetic instability, epigenetic signaling (stromal-epithelial interactions) in relation to cancer therapy and diagnosis. Because most cancers arise through multiple signaling pathways, and are heterogeneous, the identification of appropriate biomarker profiles provides a number of strategic advantages over a single biomarker. Complex networks of signaling pathways lead to increased cell proliferation, decreased cell adhesion, cellular differentiation, genetic instability, and other functions associated with the malignant phenotype. The purpose of this presentation is to illustrate the fundamental concepts for biomarker(s) selection and profile analysis of high level phenotypic biomarkers detection and potential application to other organs such as the prostate to select individuals with a negative biopsy who require further evaluation and rebiopsy.
Profiles
for Individual
Risk
Assessment
and Prostate
Cancer
George P. Hemstreet, III, MD, PhD, Omaha, NE Recent results demonstrating the effectiveness of Finesteride for preventing or delaying prostate cancer and on going clinical studies such as the SELECT Trial emphasize the need for identifying and monitoring patients for chemoprevention therapy. Molecular “fingerprints” in organs at risk for cancer years in advance of clinically manifest disease can be detected utilizing single cell proteomics. Single cell proteomics provides the opportunity not only to study protein profiles in single cells but the ability to elucidate signaling pathways relevant to the premalignant process and the identification of molecular pathways relevant to treatment selection. The objective of this presentation is to provide a succinct overview of our experience with the selection of biomarkers for prostate cancer. Spectroscopy provides an accurate and sensitive method for quantitative single cell proteomics. Improved and more stable fluorescence probes and improved quantitative analysis of protein markers at the single cell level will enhance the utility of cellular chemistry. Single cell proteomics also facilitate the study of genetic instability, epigenetic signaling (stromal-epithelial interactions) in relation to cancer therapy and diagnosis. Because most cancers arise through multiple signaling pathways, and are heterogeneous, the identification of appropriate biomarker profiles provides a number of strategic advantages over a single biomarker. Complex networks of signaling pathways lead to increased cell proliferation, decreased cell adhesion, cellular differentiation, genetic instability, and other functions associated with the malignant phenotype. The purpose of this presentation is to illustrate the fundamental concepts for biomarker(s) selection and profile analysis of high level phenotypic biomarkers detection and potential application to other organs such as the prostate to select individuals with a negative biopsy who require further evaluation and rebiopsy.